Tapan Kadia, MD, of The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the use of FLT3 inhibitors in the treatment of acute myeloid leukemia (AML). Dr Kadia talks about midostaurin in combination with standard 7+3 chemotherapy, a frontline treatment given to patients with newly diagnosed AML which has demonstrated survival benefit. Dr Kadia further talks about the use of FLT3 inhibitors in the relapsed/refractory setting as well as post-transplant, both which have shown to improve overall survival. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.

свернуть